Similar articles

• Letter: In-vitro minocycline activity against tetracycline-resistant Staphylococcus aureus.

  Chattopadhyay B, Harding E. Chattopadhyay B, et al. Lancet. 1975 Feb 15;1(7903):405. doi: 10.1016/s0140-6736(75)91333-1. Lancet. 1975. PMID: 46562 No abstract available.
• Letter: In-vitro minocycline activity against tetracycline-resistant staphylococcus aureus.

  Mitchell AA. Mitchell AA. Lancet. 1975 Mar 8;1(7906):576. doi: 10.1016/s0140-6736(75)91595-0. Lancet. 1975. PMID: 47049 No abstract available.
• Differences in susceptibility of Enterobacteriaceae and penicillin-resistant Staphylococcus aureus to tetracycline and minocycline.

  Candanoza C, Ellner PD. Candanoza C, et al. Antimicrob Agents Chemother. 1975 Mar;7(3):227-8. doi: 10.1128/AAC.7.3.227. Antimicrob Agents Chemother. 1975. PMID: 1040464 Free PMC article.
• Minocycline.

  Allen JC. Allen JC. Ann Intern Med. 1976 Oct;85(4):482-7. doi: 10.7326/0003-4819-85-4-482. Ann Intern Med. 1976. PMID: 788583 Review.
• Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.

  Felmingham D. Felmingham D. J Chemother. 2005 Aug;17 Suppl 1:5-11. doi: 10.1179/joc.2005.17.Supplement-1.5. J Chemother. 2005. PMID: 16285353 Review.